GlassScriptPhysician profile
Ronald C Koe
NPI 1942243324
$95,610.68
in general payments reported to CMS, 2019-2025
33 companies · $2,377 in 2025
The $2,377 reported for 2025 was more than what a typical Orthopaedic Surgery provider received nationally (typical 2025 total: $569).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $31K · 2020: $8,037 · 2021: $3,970 · 2022: $9,128 · 2023: $37K · 2024: $4,388 · 2025: $2,377.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Royalty Or License: $26K · Food and Beverage: $17K · Consulting Fee: $561.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Royalty Or License | $26,000.00 |
| Food and Beverage | $16,879.73 |
| Consulting Fee | $560.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Smith+Nephew, INC. | $47,893.47 | 2019-2025 | Bone Anchors With Arthroscopic Delivery System, Bioinductive Implant With Arthroscopic Delivery System - Medium, Healicoil |
| Maxx Orthopedics, INC. | $34,178.33 | 2023-2024 | |
| Conformis, INC. | $3,442.64 | 2020-2022 | |
| Trice Medical, INC. | $1,900.00 | 2019 | |
| Depuy Synthes Sales INC. | $1,701.53 | 2019-2025 | Vivigen Mis Delivery System, Monovisc, Teligen |
| Ossio INC | $1,336.50 | 2024 | |
| Miach Orthopaedics, INC. | $1,070.70 | 2023-2025 | |
| Xiros INC | $854.62 | 2021-2023 | |
| Pacira Therapeutics, INC. | $699.77 | 2019-2021 | |
| Goode Surgical INC | $534.71 | 2019-2024 | |
| Ortho Development Corporation | $285.17 | 2019 | |
| Lifenet Health | $281.40 | 2022-2023 | |
| Pavmed INC. | $255.22 | 2022 | |
| Organogenesis INC. | $205.94 | 2020-2021 | |
| Stryker Corporation | $178.98 | 2019-2025 | Alphavent |
Show all 33 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Medtronic USA, INC. | $165.30 | 2019-2020 | |
| Arteriocyte Medical Systems, INC. | $152.88 | 2021 | |
| Sanara Medtech INC. | $67.54 | 2021-2024 | Celleraterx |
| Bioventus LLC | $60.65 | 2019-2020 | |
| Ethicon US, LLC | $52.79 | 2019-2022 | |
| Paratek Pharmaceuticals, INC. | $42.46 | 2023-2024 | Nuzyra |
| Sanofi-Aventis U.S. LLC | $38.82 | 2023 | |
| Pacira Pharmaceuticals Incorporated | $26.49 | 2019-2021 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $22.03 | 2024 | Relistor |
| Avanos Medical | $21.55 | 2019 | |
| Aroa Biosurgery Incorporated | $21.50 | 2025 | |
| Dynasplint Systems INC. | $21.40 | 2020 | |
| Forte Bio-Pharma LLC | $21.32 | 2022 | |
| Vericel Corporation | $20.39 | 2022 | |
| Genzyme Corporation | $18.08 | 2023 | |
| Ferring Pharmaceuticals INC. | $15.63 | 2022 | |
| Zyla Life Sciences, INC. | $12.26 | 2019 | |
| Orthofix Medical, INC. | $10.61 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
Research and ownership
$200,000.00 in ownership or investment interests, as reported to CMS. These are holdings a clinician or an immediate family member has in a company, not payments received.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Ronald Koe listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.